Search
Osemozotan
go.drugbank.com/drugs/DB05339ExperimentalMN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD)
Muparfostat
go.drugbank.com/drugs/DB05808InvestigationalMuparfostat (PI-88) is a mixture of highly sulfated, monophosphorylated mannose oligosaccharides, derived from the extracellular phosphomannan of the yeast Pichia (Hansenula) holstii, with potential antiangiogenic
CY301
go.drugbank.com/drugs/DB06382ExperimentalCY301 (Simplivir) is an investigational gene silencing compound developed by CytoGenix for the treatment of HSV.
Efprezimod alfa
go.drugbank.com/drugs/DB16448InvestigationalCD24Fc is a biological immunomodulator originally developed to address graft-versus-host disease in stem cell transplantation in leukemia patients.
Flupirtine
go.drugbank.com/drugs/DB06623InvestigationalIt was approved for the treatment of pain in 1984 in Europe. It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.
SLx-4090
go.drugbank.com/drugs/DB05678InvestigationalSLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment of type 2 diabetes. [A33218]
P54
go.drugbank.com/drugs/DB05451ExperimentalIt inhibits the induction of the enzyme NFkB, thereby inhibiting downstream inflammatory genes such as COX II and iNOS. … P54 reduces the inflammation associated with cancer/tumors, Crohn's disease, inflammatory bowel disease, osteoarthritis, and ulcerative colitis.
Echinacoside
go.drugbank.com/drugs/DB15488Investigational[A184577] Echinacoside has demonstrated inhibition of apoptosis in neural cell lines, demonstrating potential for use in the treatment of neurological conditions.[A184592] … Echinacoside is a phenylethanoid glycoside isolated from _Echinacea angustifolia_ in 1950, and currently being investigated for the treatment of Parkinson's, Alzheimer's, atherosclerosis, osteoporosis,
Tesevatinib
go.drugbank.com/drugs/DB11973InvestigationalTesevatinib inhibits the EGF, HER2, and VEGF RTKs, each of which is a target of currently approved cancer therapies. … In cell culture models, tesevatinib retains significant potency against mutant EGFRs that are resistant to current EGFR inhibitors.
Categories: Receptor, EphB4, antagonists & inhibitors, Receptor, ErbB-2, antagonists & inhibitors